Erratum to: Cancer Chemother Pharmacol (2016) 77:413–427 DOI 10.1007/s00280-016-2960-7
The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading.
The conclusion section should read as:
Our results show that the continuous intake of ART for 4 weeks in doses up to 200 mg daily was well tolerated concerning neuro-audiological function at all three doses tested in patients with metastatic or locally advanced breast cancer. However, a temporary dose-limiting vertigo was observed, two patients experienced ongoing subclinical hearing loss and another one an ongoing tinnitus. Therefore, regular audiological assessments should be included in clinical studies investigating oral ART in the treatment of cancer patients.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s00280-016-2960-7.
Rights and permissions
About this article
Cite this article
König, M., von Hagens, C., Hoth, S. et al. Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother Pharmacol 77, 1321 (2016). https://doi.org/10.1007/s00280-016-3023-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-016-3023-9